Patents by Inventor Ida Hilden

Ida Hilden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161)
    Patent number: 11279771
    Abstract: The application discloses bispecific TFPI antibodies that are capable of specifically and simultaneously binding two epitopes within TFPI (1-161). Such bispecific antibodies strongly enhance thrombin generation by neutralising TFPI, even where the concentration of TFPI is elevated. Bispecific antibodies of the invention or compositions comprising them may be used for the treatment of subjects with a coagulopathy.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: March 22, 2022
    Assignee: NOVO NORDISK A/S
    Inventors: Helle Heibroch Petersen, Berit Olsen Krogh, Jens Breinholt, Mikael Kofod-Hansen, Ida Hilden
  • Coagulation factor-targeting to TREM-like transcript 1 (TLT-1) on activated platelets
    Patent number: 11135275
    Abstract: Described are procoagulant proteins which may, for example, be fusion proteins or chemical conjugates; methods of producing procoagulant proteins; polynucleotides that encode fusion proteins and cells that expresses them. Furthermore, described are procoagulant proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with such procoagulant proteins.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: October 5, 2021
    Assignee: Novo Nordisk Healthcare AG
    Inventors: Ida Hilden, Bernd Peschke, Jens Breinholt, Mikael Kofod-Hansen
  • Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor
    Patent number: 10717784
    Abstract: The application discloses a combination of two monospecific TFPI antibodies, wherein one antibody is capable of specifically binding TFPI (1-181) and the other antibody is capable of specifically binding TFPI (182-276), as well as bispecific anti-TFPI antibodies derived from two such monospecific antibodies. Both the combination of the two monospecific antibodies and the bispecific antibody strongly enhance thrombin generation by neutralising full length TFPI?, even where the concentration of TFPI is abnormally elevated.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: July 21, 2020
    Assignee: NOVO NORDISK A/S
    Inventors: Berit O. Krogh, Mikael Kofod-Hansen, Ida Hilden, Helle H. Petersen, Lars C. Petersen, Jens Breinholt
  • Antibodies Against Tissue Factor Pathway Inhibitor
    Publication number: 20190211112
    Abstract: The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.
    Type: Application
    Filed: March 25, 2019
    Publication date: July 11, 2019
    Inventors: Ida Hilden, Berit Olsen Krogh, Jes Thorn Clausen, Ole Hvilsted Olsen, Jens Breinholt, Brian Lauritzen, Brit Binow Soerensen
  • Coagulation factor-targeting to TLT-1 on activated platelets
    Publication number: 20190083587
    Abstract: The current invention relates to: procoagulant proteins which may, for example, be fusion proteins or chemical conjugates; methods of producing said procoagulant proteins; polynucleotides that encode said fusion proteins and cells that expresses them. Furthermore, the current invention relates to procoagulant proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with the procoagulant proteins of the current invention.
    Type: Application
    Filed: September 7, 2018
    Publication date: March 21, 2019
    Inventors: Ida Hilden, Bernd Peschke, Jens Breinholt, Mikael Kofod-Hansen
  • Targeting tissue factor to activated platelets
    Publication number: 20190062429
    Abstract: The current invention relates to procoagulant fusion proteins, polynucleotides that encode said fusion proteins and cells that expresses said fusion proteins. Furthermore, the current invention relates to fusion proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with fusions proteins of the current invention.
    Type: Application
    Filed: September 13, 2018
    Publication date: February 28, 2019
    Inventors: Ida Hilden, Lars Christian Petersen, Jens Breinholt, Mette Dahl Andersen, Jais Rose Bjelke, Thomas Egebjerg, Jes Thorn Clausen, Susanne Nedergaard Grell
  • Targeting tissue factor to activated platelets
    Patent number: 10106606
    Abstract: The current invention relates to procoagulant fusion proteins, polynucleotides that encode said fusion proteins and cells that expresses said fusion proteins. Furthermore, the current invention relates to fusion proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with fusions proteins of the current invention.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: October 23, 2018
    Assignee: Novo Nordisk A/S
    Inventors: Ida Hilden, Lars Christian Petersen, Jens Breinholt, Mette Dahl Andersen, Jais Rose Bjelke, Thomas Egebjerg, Jes Thorn Clausen, Susanne Nedergaard Grell
  • ANTIBODIES CAPABLE OF SPECIFICALLY BINDING TWO EPITOPES ON TISSUE FACTOR PATHWAY INHIBITOR
    Publication number: 20180208675
    Abstract: The application discloses a combination of two monospecific TFPI antibodies, wherein one antibody is capable of specifically binding TFPI (1-181) and the other antibody is capable of specifically binding TFPI (182-276), as well as bispecific anti-TFPI antibodies derived from two such monospecific antibodies. Both the combination of the two monospecific antibodies and the bispecific antibody strongly enhance thrombin generation by neutralising full length TFPI?, even where the concentration of TFPI is abnormally elevated.
    Type: Application
    Filed: January 9, 2018
    Publication date: July 26, 2018
    Inventors: Berit O. Krogh, Mikael Kofod-Hansen, Ida Hilden, Helle H. Petersen, Lars C. Petersen, Jens Breinholt
  • Factor VIII polypeptide titers in cell cultures
    Patent number: 9982033
    Abstract: The invention relates to a method for the production of a Factor VIII polypeptide, the method comprising the steps of a) culturing a mammalian cell expressing a Factor VIII polypeptide under conditions for expression of said Factor VIII polypeptide, said culturing conditions involving a cell culture medium comprising a C2-domain ligand, and b) isolating the expressed Factor VIII polypeptide from the mammalian cell by suitable means.
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: May 29, 2018
    Assignee: Novo Nordisk A/S
    Inventors: Laust Bruun Johnsen, Ida Hilden, Gert Bolt, Thomas Dock Steenstrup
  • Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor
    Patent number: 9896513
    Abstract: The application discloses a combination of two monospecific TFPI antibodies, wherein one antibody is capable of specifically binding TFPI (1-181) and the other antibody is capable of specifically binding TFPI (182-276), as well as bispecific anti-TFPI antibodies derived from two such monospecific antibodies. Both the combination of the two monospecific antibodies and the bispecific antibody strongly enhance thrombin generation by neutralising full length TFPI?, even where the concentration of TFPI is abnormally elevated.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: February 20, 2018
    Assignee: Novo Nordisk A/S
    Inventors: Berit O. Krogh, Mikael Kofod-Hansen, Ida Hilden, Helle H. Petersen, Lars C. Petersen, Jens Breinholt
  • ANTIBODIES CAPABLE OF BINDING TWO EPITOPES ON TISSUE FACTOR PATHWAY INHIBITOR (1-161)
    Publication number: 20170260289
    Abstract: The application discloses bispecific TFPI antibodies that are capable of specifically and simultaneously binding two epitopes within TFPI (1-161). Such bispecific antibodies strongly enhance thrombin generation by neutralising TFPI, even where the concentration of TFPI is elevated. Bispecific antibodies of the invention or compositions comprising them may be used for the treatment of subjects with a coagulopathy.
    Type: Application
    Filed: September 17, 2015
    Publication date: September 14, 2017
    Applicant: Novo Nordisk A/S
    Inventors: Helle Heibroch Petersen, Berit Olsen Krogh, Jens Breinholt, Mikael Kofod-Hansen, Ida Hilden
  • Antibodies Against Tissue Factor Pathway Inhibitor
    Publication number: 20170114147
    Abstract: The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.
    Type: Application
    Filed: January 6, 2017
    Publication date: April 27, 2017
    Inventors: Ida Hilden, Berit Olsen Krogh, Jes Thorn Clausen, Ole Hvilsted Olsen, Jens Breinholt, Brian Lauritzen, Brit Binow Soerensen
  • Antibodies against tissue factor pathway inhibitor
    Patent number: 9574011
    Abstract: The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: February 21, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Ida Hilden, Berit Olsen Krogh, Jes Thorn Clausen, Ole Hvilsted Olsen, Jens Breinholt, Brian Lauritzen, Brit Binow Soerensen
  • Targeting Tissue Factor To Activated Platelets
    Publication number: 20160272710
    Abstract: The current invention relates to procoagulant fusion proteins, polynucleotides that encode said fusion proteins and cells that expresses said fusion proteins. Furthermore, the current invention relates to fusion proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with fusions proteins of the current invention.
    Type: Application
    Filed: April 4, 2016
    Publication date: September 22, 2016
    Inventors: Ida Hilden, Lars Christian Petersen, Jens Breinholt, Mette Dahl Andersen, Jais Rose Bjelke, Thomas Egebjerg
  • Coagulation Factor-Targeting to TLT-1 on Activated Platelets
    Publication number: 20160263230
    Abstract: The current invention relates to: procoagulant proteins which may, for example, be fusion proteins or chemical conjugates; methods of producing said procoagulant proteins; polynucleotides that encode said fusion proteins and cells that expresses them. Furthermore, the current invention relates to procoagulant proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with the procoagulant proteins of the current invention.
    Type: Application
    Filed: April 8, 2016
    Publication date: September 15, 2016
    Inventors: Ida Hilden, Bernd Peschke, Jens Breinholt, Mikael Kofod-Hansen
  • Antibodies that are capable of specifically binding tissue factor pathway inhibitor
    Patent number: 9260518
    Abstract: The invention relates to antibodies that are capable of specifically binding tissue factor pathway inhibitor (TFPI), neutralising free TFPI and reducing the clotting time of blood. Furthermore, the invention relates to polynucleotides that encode such antibodies and to cells that comprise the polynucleotides or that express the antibodies of the invention. Such antibodies have utility in the treatment of subjects with a coagulopathy, alone as well as in combination with a second agent.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: February 16, 2016
    Assignee: Novo Nordisk A/S
    Inventors: Ida Hilden, Jes Thorn Clausen, Lars Christian Petersen, Brit Binow Soerensen, Helle Heibroch Petersen
  • ANTIBODIES CAPABLE OF SPECIFICALLY BINDING TWO EPITOPES ON TISSUE FACTOR PATHWAY INHIBITOR
    Publication number: 20160032012
    Abstract: The application discloses a combination of two monospecific TFPI antibodies, wherein one antibody is capable of specifically binding TFPI (1-181) and the other antibody is capable of specifically binding TFPI (182-276), as well as bispecific anti-TFPI antibodies derived from two such monospecific antibodies. Both the combination of the two monospecific antibodies and the bispecific antibody strongly enhance thrombin generation by neutralising full length TFPI?, even where the concentration of TFPI is abnormally elevated.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 4, 2016
    Inventors: Berit O. Krogh, Mikael Kofod-Hansen, Ida Hilden, Helle H. Petersen, Lars C. Petersen
  • Antibodies that are capable of specifically binding tissue factor pathway inhibitor
    Patent number: 9228022
    Abstract: The invention relates to antibodies that are capable of specifically binding tissue factor pathway inhibitor (TFPI), neutralizing free TFPI and reducing the clotting time of blood. Furthermore, the invention relates to polynucleotides that encode such antibodies and to cells that comprise the polynucleotides or that express the antibodies of the invention. Such antibodies have utility in the treatment of subjects with a coagulopathy, alone as well as in combination with a second agent.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: January 5, 2016
    Assignee: Novo Nordisk A/S
    Inventors: Ida Hilden, Jes Thorn Clausen, Lars Christian Petersen, Brit Binow Soerensen, Helle Heibroch Petersen, Anders Svensson
  • THERAPEUTIC FACTOR VIII ANTIBODIES
    Publication number: 20150239984
    Abstract: The present invention relates to therapeutic FVIII antibodies. In particular, the present invention relates to FVIII antibodies having the ability to prolong the circulatory half life of FVIII. The present invention furthermore relates to use of such antibodies in treatment and prophylaxis of haemophilia A.
    Type: Application
    Filed: May 12, 2015
    Publication date: August 27, 2015
    Applicant: NOVO NORDISK A/S
    Inventors: Henrik Oestergaard, Ida Hilden, Heidi L. Holmberg, Kasper Lamberth, Jes T. Clausen
  • Therapeutic factor VIII antibodies
    Patent number: 9062115
    Abstract: The present invention relates to therapeutic FVIII antibodies. In particular, the present invention relates to FVIII antibodies having the ability to prolong the circulatory half life of FVIII. The present invention furthermore relates to use of such antibodies in treatment and prophylaxis of haemophilia A.
    Type: Grant
    Filed: September 15, 2011
    Date of Patent: June 23, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Henrik Oestergaard, Ida Hilden, Heidi Lindgreen Holmberg, Kasper Lamberth, Jes Thorn Clausen